Memo Therapeutics AG

Memo Therapeutics AG is a Swiss-based biotechnology startup founded in 2012. The company stands out as an innovator in the antibody discovery and immune repertoire analysis field. Its proprietary platform, DROPZYLLA™, creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. This revolutionary approach results in the generation of large and relevant antibody libraries that are expected to contain an unprecedented number of relevant and rare antibodies. Memo Therapeutics' business strategy focuses on the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. The company's technology, DROPZYLLA™, is not only deployed in proprietary antibody discovery programs but is also made available in collaborations for various applications such as screening of CAR-T; TCR-T or bi-specific antibodies. The company recently secured a noteworthy Fr.20.00M Series C investment on 07 May 2024, with Kurma Partners and Ysios Capital as the investors. This infusion of capital is expected to further fuel Memo Therapeutics' innovative efforts in the field of antibody discovery and immune repertoire analysis.